Idelalisib and duvelisib are both selective inhibitors of the delta isoform of PI3K, which have received approval from the FDA in 2014 and 2018, respectively, for the CLL and follicular lymphoma (FL) [88–90]. This evidence concerns the gene PIK3CG and B-cell chronic lymphocytic leukemia.